Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

FGFR4 (Fibroblast growth factor receptor 4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

FGFR4 expression	Ovarian Cancer	FGFR4 expression	Ovarian Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
FGFR4 mutation	Non Small Cell Lung Cancer	FGFR4 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR4 overexpression	Colorectal Cancer	FGFR4 overexpression	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
FGFR4 G388R	Neuroendocrine Tumor	FGFR4 G388R	Neuroendocrine Tumor	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
FGFR4 G388R + NOS3 rs2070744	Hepatocellular Cancer	FGFR4 G388R + NOS3 rs2070744	Hepatocellular Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
FGFR4 expression	Colon Cancer	FGFR4 expression	Colon Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
FGFR4 expression	Hepatocellular Cancer	FGFR4 expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
FGFR4 mutation	Melanoma	FGFR4 mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
FGFR4 mutation	Solid Tumor	FGFR4 mutation	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR4 overexpression	Breast Cancer	FGFR4 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3